Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042.
Maas SLN, Sievers P, Weber DC, Weller M, van den Bent MJ, Mair MJ, Kros JM, Carparrotti F, von Deimling A, Salvador VF, Peerdeman SM, Casas-Martin J, Gorlia T, Sahm F, Preusser M. Maas SLN, et al. Acta Neuropathol. 2023 Dec;146(6):837-840. doi: 10.1007/s00401-023-02642-5. Epub 2023 Oct 19. Acta Neuropathol. 2023. PMID: 37855895 Free PMC article. No abstract available.
Analysis of recurrence probability following radiotherapy in patients with CNS WHO grade 2 meningioma using integrated molecular-morphologic classification.
Deng MY, Hinz F, Maas SLN, Anil G, Sievers P, Conde-Lopez C, Lischalk J, Rauh S, Eichkorn T, Regnery S, Bauer L, Held T, Meixner E, Lang K, Hörner-Rieber J, Herfarth K, Jones D, Pfister SM, Jungk C, Unterberg A, Wick W, von Deimling A, Debus J, Sahm F, König L. Deng MY, et al. Among authors: maas sln. Neurooncol Adv. 2023 May 14;5(1):vdad059. doi: 10.1093/noajnl/vdad059. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37293256 Free PMC article.
Glioblastoma lacking necrosis or vascular proliferations: Different clinical presentation but similar outcome, regardless of histology or isolated TERT promoter mutation.
Wijnenga MMJ, Maas SLN, van Dis V, Tesileanu CMS, Kros JM, Dirven L, Hazelbag HM, Dubbink HJ, Vincent AJPE, French PJ, van den Bent MJ. Wijnenga MMJ, et al. Among authors: maas sln. Neurooncol Adv. 2023 Jun 21;5(1):vdad075. doi: 10.1093/noajnl/vdad075. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37441086 Free PMC article. No abstract available.
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.
Chen WC, Choudhury A, Youngblood MW, Polley MC, Lucas CG, Mirchia K, Maas SLN, Suwala AK, Won M, Bayley JC, Harmanci AS, Harmanci AO, Klisch TJ, Nguyen MP, Vasudevan HN, McCortney K, Yu TJ, Bhave V, Lam TC, Pu JK, Li LF, Leung GK, Chan JW, Perlow HK, Palmer JD, Haberler C, Berghoff AS, Preusser M, Nicolaides TP, Mawrin C, Agnihotri S, Resnick A, Rood BR, Chew J, Young JS, Boreta L, Braunstein SE, Schulte J, Butowski N, Santagata S, Spetzler D, Bush NAO, Villanueva-Meyer JE, Chandler JP, Solomon DA, Rogers CL, Pugh SL, Mehta MP, Sneed PK, Berger MS, Horbinski CM, McDermott MW, Perry A, Bi WL, Patel AJ, Sahm F, Magill ST, Raleigh DR. Chen WC, et al. Among authors: maas sln. Nat Med. 2023 Dec;29(12):3067-3076. doi: 10.1038/s41591-023-02586-z. Epub 2023 Nov 9. Nat Med. 2023. PMID: 37944590 Free PMC article.
Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial.
Deng MY, Maas SLN, Hinz F, Karger CP, Sievers P, Eichkorn T, Meixner E, Hoegen-Sassmannshausen P, Hörner-Rieber J, Lischalk JW, Seidensaal K, Bernhardt D, Jungk C, Unterberg A, Wick A, Wick W, von Deimling A, Sahm F, Combs S, Herfarth K, Debus J, König L. Deng MY, et al. Among authors: maas sln. Neuro Oncol. 2024 Apr 5;26(4):701-712. doi: 10.1093/neuonc/noad244. Neuro Oncol. 2024. PMID: 38079455 Clinical Trial.
Meningioma: International Consortium on Meningiomas (ICOM) consensus review on scientific advances & treatment paradigms for clinicians, researchers, and patients.
Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R, Yefet LS, Tonn JC, Gui C, Ostrom QT, Barnholtz-Sloan J, Perry A, Ellenbogen Y, Hanemann CO, Jungwirth G, Jenkinson MD, Tabatabai G, Mathiesen TI, McDermott MW, Tatagiba M, la Fougère C, Maas SLN, Galldiks N, Albert NL, Brastianos PK, Ehret F, Minniti G, Lamszus K, Ricklefs FL, Schittenhelm J, Drummond KJ, Dunn IF, Pathmanaban ON, Cohen-Gadol A, Sulman EP, Tabouret E, Le Rhun E, Mawrin C, Moliterno J, Weller M, Bi WL, Gao A, Yip S, Niyazi M; International Consortium on Meningiomas (ICOM); Aldape K, Wen PY, Short S, Preusser M, Nassiri F, Zadeh G. Wang JZ, et al. Among authors: maas sln. Neuro Oncol. 2024 May 2:noae082. doi: 10.1093/neuonc/noae082. Online ahead of print. Neuro Oncol. 2024. PMID: 38695575
Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.
van Opijnen MP, Broekman MLD, Cuppen E, Dubbink HJ, Ter Elst A, van Eijk R, Mühlebner A, Jansen C, van der Geize R, Speel EM, Groenen PJTA, de Vos FYF, Wesseling P, de Leng WWJ, Maas SLN. van Opijnen MP, et al. Among authors: maas sln. J Neurooncol. 2024 Feb;166(3):485-492. doi: 10.1007/s11060-024-04568-8. Epub 2024 Jan 29. J Neurooncol. 2024. PMID: 38285243 Free PMC article. Review.
Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study.
van Opijnen MP, Broekman MLD, de Vos FYF, Cuppen E, van der Hoeven JJM, van Linde ME, Compter A, Beerepoot LV, van den Bent MJ, Vos MJ, Fiebrich HB, Koekkoek JAF, Hoeben A, Kho KH, Driessen CML, Jeltema HR, Robe PAJT, Maas SLN. van Opijnen MP, et al. Among authors: maas sln. BMC Med Genomics. 2022 Nov 4;15(1):233. doi: 10.1186/s12920-022-01343-4. BMC Med Genomics. 2022. PMID: 36333718 Free PMC article.
38 results